Hutchmed (China) Treatment Approved in China for Pancreatic Tumors
June 18 2021 - 12:00PM
Dow Jones News
By Joe Hoppe
Hutchmed (China) Ltd. said Friday that its pancreatic
neuroendocrine tumor treatment, surufatinib, has been granted
approval for drug registration by the National Medical Products
Administration of China.
The biopharmaceutical company said that surufatinib was
previously approved by China for the treatment of nonpancreatic
neuroendocrine tumors in December. The drug is marketed under the
brand name Sulanda in China.
Shares at 1525 GMT were up 31.0 pence, or 8.0%, at 417.0
pence.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
June 18, 2021 11:49 ET (15:49 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
HUTCHMED China (NASDAQ:HCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
HUTCHMED China (NASDAQ:HCM)
Historical Stock Chart
From Apr 2023 to Apr 2024
